AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
Zimmer Biomet's (ZBH) Pandemic Recovery Slow, Margin Woes Stay
by Zacks Equity Research
The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) strong segmental performance and bullish 2022 outlook.
Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from a robust payment accuracy business. However, intense competition remains a woe.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Why the Earnings Surprise Streak Could Continue for AMN Healthcare (AMN)
by Zacks Equity Research
AMN Healthcare (AMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DaVita's (DVA) New Buyout to Enhance Transplant Experience
by Zacks Equity Research
DaVita (DVA) acquires MedSleuth which will help simplify the kidney transplant process and provide patients greater access to transplantation.
Here's Why You Should Hold SmileDirectClub (SDC) Stock for Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub (SDC), backed by its expansion in the teledentistry space and the long-term growth target.
Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise
by Zacks Equity Research
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
Quest Diagnostics (DGX) Expands Extended Care With New Buyout
by Zacks Equity Research
This latest acquisition builds on Quest Diagnostics' (DGX) 2018 acquisition of Mobile Medical Examination Service (MedXM), a provider of home-based health risk assessments and related services.
Abbott's (ABT) Organic Base Sales Grow Amid COVID Case Surge
by Zacks Equity Research
Even though COVID-19 case rates are surging, Abbott (ABT) is registering growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
What's in Store for Intuitive Surgical's (ISRG) Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.
Inari Medical (NARI) Posts Solid Preliminary Q4, FY2021 Revenues
by Zacks Equity Research
Inari Medical (NARI) posts solid fourth-quarter and full-year 2021 revenue data, courtesy of resilience shown in the face of the COVID-19 induced challenges.
Here's Why You Should Hold on to Walgreens Boots (WBA) for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots' (WBA) robust growth in the International segment and strong first-quarter fiscal 2022 results.
QIAGEN (QGEN) to Boost Testing Capacity With Liquid-Based Kit
by Zacks Equity Research
QIAGEN's (QGEN) artus SARS-CoV-2 Prep&Amp UM is faster than standard processes and can spot the virus more reliably, including the new Omicron variant.
Zacks Industry Outlook Highlights: AMN Healthcare Services, Apollo Medical Holdings, Inc. and LifeMD, Inc
by Zacks Equity Research
AMN Healthcare Services, Apollo Medical Holdings, Inc. and LifeMD, Inc are highlighted in this Industry Outlook article.
AMN Healthcare Services (AMN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $108.34, marking a +1.88% move from the previous day.
Looking for a Growth Stock? 3 Reasons Why AMN Healthcare (AMN) is a Solid Choice
by Zacks Equity Research
AMN Healthcare (AMN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
IDEXX (IDXX) Collaborates With PetDx for Canine Cancer Test
by Zacks Equity Research
Following the partnership between IDEXX (IDXX) and PetDx , the test is likely to be available later in January to all veterinary customers of IDXX in the United States and Canada.
Intuitive Surgical (ISRG) Posts Robust Preliminary Q4 Results
by Zacks Equity Research
Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2021 results driven primarily by da Vinci procedure volume growth.
PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues
by Zacks Equity Research
PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.
Medtronic's (MDT) DTM SCS Endurance Therapy Study Data Positive
by Zacks Equity Research
Medtronic's (MDT) DTM SCS endurance therapy offers meaningful clinical benefits by reducing pain, improving quality of life and offering meaningful device longevity for patients.
Zacks Industry Outlook Highlights: AMN Healthcare Services, Apollo Medical Holdings, Inc and LifeMD, Inc
by Zacks Equity Research
AMN Healthcare Services, Apollo Medical Holdings, Inc and LifeMD, Inc are highlighted in this industry outlook article.
AMN Healthcare (AMN) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
AMN Healthcare's (AMN) solid fourth-quarter results are likely to have been boosted by solid segmental performances.